Cardiovascular Adverse Events with Anti-CD38 Antibodies Added to Identical Myeloma Regimens: A Systematic Review and Meta- analysis

For decades, doctors have relied on a specific class of drugs to fight multiple myeloma, a cancer of the blood that primarily affects older adults. These treatments work by targeting a protein on the surface of cancer cells, effectively flagging them for destruction by the body's own immune system. Because these drugs are so effective at controlling the cancer, they are now a standard part of care, often given alongside other medications in long-term treatment plans. However, because these patients are older and often receive treatment for extended periods, doctors have long been concerned about the toll these powerful therapies might take on the heart. While the benefits for survival are clear, the picture of potential heart risks has remained somewhat blurry, with previous studies focusing more on common side effects like high blood pressure rather than rare but serious cardiac events.

A team of researchers set out to clear up this uncertainty by looking at the data from a large collection of clinical trials. They focused specifically on studies where the only difference between the treatment group and the control group was the addition of the anti-cancer antibody. This design is crucial because it acts like a controlled experiment: since both groups received the exact same background medications, any difference in heart problems could be traced directly to the antibody itself. The researchers gathered information from twenty-five different trials involving nearly seven thousand participants. They did not rely on the summaries published in medical journals, which often list only the most frequent side effects. Instead, they went directly to the raw, detailed records submitted to government regulators and clinical trial registries, which list every single serious event that occurred, no matter how rare.

The analysis revealed a distinct pattern. When the antibody was added to the treatment regimen, there was a noticeable increase in the number of serious heart-related events compared to the group that did not receive it. Specifically, the data showed a higher frequency of ischemic heart disease, a condition where blood flow to the heart muscle is reduced, as well as a rise in arterial clots and serious cardiac adverse events. The researchers also found that patients receiving the antibody were more likely to develop high blood pressure that did not require hospitalization. These findings suggest that the antibody may place additional strain on the cardiovascular system, or perhaps that the longer duration of treatment allowed more time for these issues to develop, though the study could not definitively separate these two possibilities.

However, the story is not one of clear-cut danger for every heart condition. When the researchers looked at two other major concerns—irregular heartbeats known as atrial fibrillation and heart failure—they found the results were much less certain. The data for these conditions was too scattered to draw a firm conclusion; the numbers fluctuated in a way that could mean a slight increase, a slight decrease, or no change at all. Because the study relied on counting events reported by doctors rather than a strict, independent review of every heart case, the researchers emphasized that these signals need further confirmation. They noted that the studies often excluded patients who already had significant heart disease, meaning the results might not apply to everyone with a history of cardiac issues.

Ultimately, the work serves as an important alert rather than a final verdict. It suggests that while these antibodies are powerful tools against cancer, they may carry a hidden cost in the form of increased vascular and heart risks that requires closer monitoring. The authors stress that this does not mean doctors should stop using these life-saving drugs, but rather that they should remain vigilant. Patients and clinicians need to balance the proven benefit of controlling the cancer against these emerging signals of heart stress, perhaps paying closer attention to blood pressure and heart symptoms during treatment. The study concludes that future research needs to be more precise, tracking exactly when heart events happen and how long patients are on treatment, to fully understand the relationship between these drugs and heart health.